• Something wrong with this record ?

The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction

I Papezikova, M Pekarova, M Chatzopoulou, I Nicolaou, V Demopoulos, L Kubala, A Lojek

. 2008 ; 29 (5) : 775-778.

Language English Country Sweden

Document type Research Support, Non-U.S. Gov't

OBJECTIVES: An increased glucose utilization by aldose reductase (ALR-2) has been implicated in the pathogenesis of diabetic vascular complications. In this process, several mechanisms are involved, including the depletion of cofactors required for the action of antioxidant enzymes or endothelial NO synthase. In this study, the effect of a novel ALR-2 inhibitor JMC-2004 on hyperglycemia-induced endothelial dysfunction was studied. METHODS: Bovine aortic endothelial cells (BAEC) were treated with glucose (30 mM), JMC-2004 (0.01mM), or glucose and JMC-2004 for 24 h. The cells were then stimulated with calcium ionophore A23187 after which NO production was measured electrochemically using a porphyrine-coated carbon NO electrode. Nitrite concentrations were determined in the cell supernatants. The peroxyl and hydroxyl radical-scavenging activity of JMC-2004 was measured with luminol-enhanced chemiluminescence. The expression of eNOS was determined by Western blotting. JMC-2004 IC50 for ALR-2 was determined colorimetrically with D-glyceraldehyde as a substrate. RESULTS: Incubating the cells with 30 mM glucose strongly diminished A23187- induced NO production. Treatment with JMC-2004 restored NO production by 40% without affecting eNOS expression. This effect was probably antioxidantindependent, since JMC-2004 did not have any antioxidant capacity. JMC-2004 exerted high selectivity towards ALR-2. CONCLUSIONS: ALR-2 inhibition with JMC-2004 was able to abolish hyperglycemia- induced endothelial dysfunction in bovine aortic endothelial cells.

000      
02525naa 2200541 a 4500
001      
bmc11006273
003      
CZ-PrNML
005      
20120907082855.0
008      
110401s2008 sw e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Papežíková, Ivana $7 xx0098961
245    14
$a The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction / $c I Papezikova, M Pekarova, M Chatzopoulou, I Nicolaou, V Demopoulos, L Kubala, A Lojek
314    __
$a Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic. ivanah@ibp.cz
520    9_
$a OBJECTIVES: An increased glucose utilization by aldose reductase (ALR-2) has been implicated in the pathogenesis of diabetic vascular complications. In this process, several mechanisms are involved, including the depletion of cofactors required for the action of antioxidant enzymes or endothelial NO synthase. In this study, the effect of a novel ALR-2 inhibitor JMC-2004 on hyperglycemia-induced endothelial dysfunction was studied. METHODS: Bovine aortic endothelial cells (BAEC) were treated with glucose (30 mM), JMC-2004 (0.01mM), or glucose and JMC-2004 for 24 h. The cells were then stimulated with calcium ionophore A23187 after which NO production was measured electrochemically using a porphyrine-coated carbon NO electrode. Nitrite concentrations were determined in the cell supernatants. The peroxyl and hydroxyl radical-scavenging activity of JMC-2004 was measured with luminol-enhanced chemiluminescence. The expression of eNOS was determined by Western blotting. JMC-2004 IC50 for ALR-2 was determined colorimetrically with D-glyceraldehyde as a substrate. RESULTS: Incubating the cells with 30 mM glucose strongly diminished A23187- induced NO production. Treatment with JMC-2004 restored NO production by 40% without affecting eNOS expression. This effect was probably antioxidantindependent, since JMC-2004 did not have any antioxidant capacity. JMC-2004 exerted high selectivity towards ALR-2. CONCLUSIONS: ALR-2 inhibition with JMC-2004 was able to abolish hyperglycemia- induced endothelial dysfunction in bovine aortic endothelial cells.
590    __
$a bohemika - dle Pubmed
650    _2
$a aldehydreduktasa $x antagonisté a inhibitory $7 D000449
650    _2
$a zvířata $7 D000818
650    _2
$a western blotting $7 D015153
650    _2
$a calcimycin $x farmakologie $7 D000001
650    _2
$a skot $7 D002417
650    _2
$a buněčné linie $7 D002460
650    _2
$a elektrochemie $7 D004563
650    _2
$a endoteliální buňky $x patologie $x účinky léků $7 D042783
650    _2
$a cévní endotel $x patologie $x účinky léků $7 D004730
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a glukosa $x farmakologie $7 D005947
650    _2
$a glyceraldehyd $x metabolismus $7 D005985
650    _2
$a hydroxylový radikál $x metabolismus $7 D017665
650    _2
$a hyperglykemie $x patologie $7 D006943
650    _2
$a luminiscence $7 D049449
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a synthasa oxidu dusnatého, typ III $x metabolismus $7 D052250
650    _2
$a peroxidy $x metabolismus $7 D010545
650    _2
$a fenoly $x farmakologie $7 D010636
650    _2
$a pyrroly $x farmakologie $7 D011758
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pekarová, Michaela, $d 1982-2019 $7 mub2011659519
700    1_
$a Chatzopoulou, Maria
700    1_
$a Nicolaou, Ioannis
700    1_
$a Demopoulos, Vassilis
700    1_
$a Kubala, Lukáš, $d 1973- $7 xx0094314
700    1_
$a Lojek, Antonín, $d 1954- $7 xx0063943
773    0_
$t Neuroendocrinology Letters $g Roč. 29, č. 5 (2008), s. 775-778 $x 0172-780X $w MED00168352
910    __
$a ABA008 $b x $y 2
990    __
$a 20110414101644 $b ABA008
991    __
$a 20120907083026 $b ABA008
999    __
$a ok $b bmc $g 833879 $s 698367
BAS    __
$a 3
BMC    __
$a 2008 $b 29 $c 5 $d 775-778 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
LZP    __
$a 2011-1B09/dkjt

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...